Tyra Biosciences (Tyra Biosciences) Scaled Net Operating Assets : 0.06 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Tyra Biosciences Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Tyra Biosciences's operating assets for the quarter that ended in Mar. 2024 was $22.28 Mil. Tyra Biosciences's operating liabilities for the quarter that ended in Mar. 2024 was $8.38 Mil. Tyra Biosciences's Total Assets for the quarter that ended in Dec. 2023 was $225.86 Mil. Therefore, Tyra Biosciences's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2024 was 0.06.

Tyra Biosciences Scaled Net Operating Assets Historical Data

The historical data trend for Tyra Biosciences's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tyra Biosciences Scaled Net Operating Assets Chart

Tyra Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Scaled Net Operating Assets

-8.71

-54.39

0.05

0.03

Tyra Biosciences Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Scaled Net Operating Assets	Get a 7-Day Free Trial												0.04	0.05	0.05	0.03	0.06

Competitive Comparison of Tyra Biosciences's Scaled Net Operating Assets

For the Biotechnology subindustry, Tyra Biosciences's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tyra Biosciences's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tyra Biosciences's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Tyra Biosciences's Scaled Net Operating Assets falls into.

Tyra Biosciences Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Tyra Biosciences's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2023 )
=	(Operating Assets (A: Dec. 2023 )	-	Operating Liabilities (A: Dec. 2023 ))	/	Total Assets (A: Dec. 2022 )
=	(22.388	-	15.099)	/	266.181
=	0.03

where

	Operating Assets		(A: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	225.857	-	203.469
=	22.388

	Operating Liabilities		(A: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	21.595	-	6.216	-	0.28
=	15.099

Tyra Biosciences's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2024 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Mar. 2024 )
=	(Operating Assets (Q: Mar. 2024 )	-	Operating Liabilities (Q: Mar. 2024 ))	/	Total Assets (Q: Dec. 2023 )
=	(22.279	-	8.375)	/	225.857
=	0.06

where

	Operating Assets		(Q: Mar. 2024 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	404.741	-	382.462
=	22.279

	Operating Liabilities		(Q: Mar. 2024 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	14.862	-	6.117	-	0.37
=	8.375

Tyra Biosciences Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Tyra Biosciences's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Tyra Biosciences (Tyra Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tyra Biosciences Inc (NAS:TYRA) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

2656 State Street, Carlsbad, CA, USA, 92008

Website

https://www.tyra.bio

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. Its lead product candidate is TYRA-300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).

Executives

Daniel Bensen	officer: Chief Operating Officer	C/O TYRA BIOSCIENCES, INC, 2656 STATE STREET, CARLSBAD CA 92008
Todd Harris	director, officer: Chief Executive Officer	30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Mva Investors, Llc	10 percent owner	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Aaron I. Davis	10 percent owner	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Alan Fuhrman	officer: Chief Financial Officer	C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
Ali D. Fawaz	officer: General Counsel and Secretary	C/O TYRA BIOSCIENCES, INC., 2656 STATE STREET, CARLSBAD CA 92008
John Stephen Healy	officer: General Counsel and Secretary	C/O TYRA BIOSCIENCES, INC., 2656 STATE STREET, CARLSBAD CA 92008
Boxer Capital, Llc	10 percent owner	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Robert J More	director, 10 percent owner	680 S CACHE STREET, SUITE 100, BOX 10820, JACKSON WY 83001
Alta Partners Nextgen Fund Ii, L.p.	10 percent owner	4 EMBARCADERO CENTER, SUITE 2100, SAN FRANCISCO CA 94111
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Robert L. Hudkins	officer: Chief Technology Officer	C/O TYRA BIOSCIENCES, INC, 2656 STATE STREET, CARLSBAD CA 92008
Siddarth Subramony	director	C/O TYRA BIOSCIENCES, INC, 2656 STATE STREET, CARLSBAD CA 92008
Melissa Mccracken	director	C/O TYRA BIOSCIENCES, INC, 2656 STATE STREET, CARLSBAD CA 92008